Fagan Dedra H, Yee Douglas
Department of Pharmacology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):423-9. doi: 10.1007/s10911-008-9098-0. Epub 2008 Nov 12.
After the discovery that depriving certain breast tumors of estrogen promoted tumor regression, therapeutic strategies aimed at depriving tumors of this hormone were developed. The tumorigenic properties of estrogen are regulated through the estrogen receptor-alpha (ER), making understanding the mechanisms that activate this receptor highly relevant. In addition to estrogen activating the ER, other growth factor pathways, such as the insulin-like growth factors (IGFs), can activate the ER. This review will examine the interaction between these two pathways. Estrogen can activate the growth stimulatory properties of the IGF pathway via ER's genomic and non-genomic functions. Further, blockade of ER function can inhibit IGF-mediated mitogenesis and blocking IGF action can inhibit estrogen stimulation of breast cancer cells. Collectively, these observations suggest that the two growth regulatory pathways are tightly linked and a more thorough understanding of the mechanism of this crosstalk could lead to improved therapeutic strategies in breast cancer.
在发现剥夺某些乳腺肿瘤的雌激素可促进肿瘤消退后,旨在剥夺肿瘤这种激素的治疗策略得以开发。雌激素的致瘤特性通过雌激素受体α(ER)进行调节,因此了解激活该受体的机制具有高度相关性。除了雌激素激活ER外,其他生长因子途径,如胰岛素样生长因子(IGF),也可激活ER。本综述将探讨这两条途径之间的相互作用。雌激素可通过ER的基因组和非基因组功能激活IGF途径的生长刺激特性。此外,阻断ER功能可抑制IGF介导的有丝分裂,而阻断IGF作用可抑制雌激素对乳腺癌细胞的刺激。总体而言,这些观察结果表明这两条生长调节途径紧密相连,更深入地了解这种相互作用的机制可能会带来改进的乳腺癌治疗策略。